Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis UCSD UCSF
Dates
study started
study ends around
Principal Investigator
by Thomas Martin (ucsf)
Headshot of Thomas Martin
Thomas Martin

Description

Summary

Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.

Official Title

Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Details

Keywords

Multiple Myeloma, CAR-T cells, Rimiducid may be administered as indicated

Eligibility

You can join if…

Open to people ages 18 years and up

  • Subjects who have received P-BCMA-101 and completed or discontinued early from a Poseida sponsored treatment protocol.
  • Subject has provided informed consent.

You CAN'T join if...

  • None

Locations

  • University of California Davis
    Davis California 95618 United States
  • University of California, San Diego
    San Diego California 92121 United States
  • University of California San Francisco
    San Francisco California 94143 United States

Lead Scientist at University of California Health

  • Thomas Martin (ucsf)
    A leading expert in hematology-oncology, Dr. Thomas Martin is associate director of UCSF's myeloma program and director of the unrelated donor transplantation programs for adults at UCSF Medical Center. Martin is clinical research director of hematologic malignancies (blood cancers) at the UCSF Helen Diller Family Comprehensive Cancer Center.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Poseida Therapeutics, Inc.
ID
NCT03741127
Phase
Phase 1 Multiple Myeloma Research Study
Study Type
Interventional
Participants
Expecting 100 study participants
Last Updated